Jefferies Financial Group Inc. Sells 17,021 Shares of Medpace Holdings, Inc. $MEDP

Jefferies Financial Group Inc. trimmed its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 67.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,232 shares of the company’s stock after selling 17,021 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Medpace were worth $4,233,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in MEDP. Quent Capital LLC acquired a new stake in Medpace during the third quarter worth approximately $25,000. Optiver Holding B.V. bought a new stake in Medpace in the third quarter worth approximately $27,000. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the period. Employees Retirement System of Texas acquired a new position in Medpace in the second quarter valued at approximately $36,000. Finally, Root Financial Partners LLC bought a new position in shares of Medpace during the 3rd quarter worth approximately $38,000. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 1.7%

MEDP stock opened at $478.54 on Tuesday. The firm has a market capitalization of $13.58 billion, a PE ratio of 31.28, a P/E/G ratio of 2.26 and a beta of 1.44. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92. The stock’s 50 day moving average is $532.11 and its 200-day moving average is $539.65.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same quarter in the prior year, the business posted $3.67 EPS. The business’s revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Mizuho set a $582.00 target price on shares of Medpace in a research note on Wednesday, February 11th. Royal Bank Of Canada assumed coverage on shares of Medpace in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price target for the company. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a report on Friday, February 13th. Finally, Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a research report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.